云克治疗类风湿关节炎患者合并骨质疏松的临床疗效观察  

The clinical observation of ^(99)Tc-MDP in the treatment of rheumatoid arthritis patients with osteoporosis

作　　者：邹瑶 肖伟[1] 任翔 ZOU Yao;XIAO Wei;REN Xiang(The First People’s Hospital of Changde City, Changde 415000, China)

机构地区：[1]常德市第一人民医院,湖南常德415000

出　　处：《中国骨质疏松杂志》2021年第6期848-850,861,共4页Chinese Journal of Osteoporosis

摘　　要：目的分析云克治疗类风湿关节炎(rheumatoid arthritis,RA)患者合并骨质疏松的临床疗效。方法选取我院2019年1月1日至2019年3月31日住院接受云克治疗的RA患者49名及未接受云克治疗的RA门诊患者30名并随访一年,收集患者临床资料。结果两组患者基线临床资料年龄、病程、体质量指数、晨僵时间、疼痛评分、ESR、CRP、RF、骨密度、关节肿胀及压痛数目差异无统计学意义(P>0.05)。使用云克治疗的研究组患者在治疗1年后各项临床指标均低于对照组(P<0.05)。研究组经云克治疗后12个月骨密度有所改善(P<0.05),而对照组治疗前后腰椎及髋部BMD对比差异无统计学意义(P>0.05)。结论云克治疗类风湿关节炎合并骨质疏松不仅有良好的抗炎效果,亦可增加骨密度、抗骨质疏松。Objective To evaluate the clinical efficacy of ^(99)Tc-MDP in the treatment of rheumatoid arthritis patients with osteoporosis.Methods 49 inpatients who were treated with99Tc-MDP and 30 outpatients were selected and followed up for one year,and collected the clinical data.Results There were no significant differences in the baseline clinical data of the two groups of patients with age,course of disease,BMI,morning stiffness time,VAS,ESR,CRP,RF,bone mineral density,the number of joint swelling and tenderness(P>0.05).The clinical indicators of patients in the study group treated with99Tc-MDP were lower than those in the control group after one year of treatment(P<0.05).The bone mineral density of the study group had improved after 12 months of ^(99)Tc-MDP treatment(P<0.05),while the control group had no significant difference in lumbar spine and femoral neck BMD before and after treatment(P>0.05).Conclusion ^(99)Tc-MDP can relieve inflammatory and increase bone mineral density in in the treatment of rheumatoid arthritis patients with osteoporosis.

关 键 词：类风湿关节炎 骨质疏松 云克 

分 类 号：R959[医药卫生—药学]